Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities

11/30/2021 | 08:08am EST

Takeda is enhancing its Corporate Social Responsibility program with significant commitment to underrepresented communities in the U.S.

U.S. Program prioritizes health equity, climate resiliency, K-8 math literacy and food security across the country

20 grantees selected as FY2021 program partners

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is enhancing its Corporate Social Responsibility (CSR) Program in the U.S., making an initial commitment of $20 million its first year supporting organizations in the U.S. to help improve equity among underrepresented communities in the areas of health, education, the environment and access to nutrition/food. Takeda also announced its current 2021 U.S. CSR Program grant recipients, including 20 organizations who will share $16,595,000 in total grants.

“Achieving better health outcomes requires a multi-faceted approach and a more holistic view of health and well-being,” said Ramona Sequeira, President, US Business Unit and Global Portfolio Commercialization, Takeda Pharmaceutical Company Limited. “Our philanthropic efforts in the U.S. focus on multiple areas including reducing social disparities, improving access to medicines and diagnosis, achieving environmental sustainability, promoting equitable educational opportunities and ensuring healthy food sources for vulnerable individuals and families. We’re looking forward to growing our U.S. CSR Program over the coming years and are proud to partner with organizations located in the communities where many of our employees live and work – including our U.S. hub in Massachusetts.”

Takeda’s U.S. CSR grant applications are reviewed by an internal review committee, on a rolling basis and approved through a formal governance process. Takeda partners with local and regional organizations who align with our philanthropic focus areas, share our values and our commitment to improving people’s lives for the better. Takeda’s 2021 U.S. CSR grantees include:

Promoting Food System Equity

Takeda is supporting the following organizations which are increasing food system equity for vulnerable families in communities around the country:

  • Daily Table – Healthy Grocer for All Program
  • Food for Free – Just Eats Program
  • Greater Boston Food Bank – Mobile Market Program
  • Northern Illinois Food Bank – Mobile Market Program
  • The Food Project – Growing Leaders, Growing Communities Program
  • West End House – Family Food Program

Promoting Greater Educational Equity

Takeda’s funding of the following organizations will help advance K-8 math programs to promote greater educational equity:

  • City Year – Boston STEM Program
  • Learn Fresh – NBA Math Hoops Program
  • Lesley University – Culturally Relevant Math Expressions Program
  • STEM Next – Million Girls Moonshot Program
  • Tutoring Plus – After School Tutoring and Mentoring Program
  • Young People’s Project – Math and STEM Literacy Program

Promoting Health Equity

Takeda is supporting the following organizations with programs aimed at creating social, physical and economic environments that promote health equity for all:

  • Boston Healthcare for the Homeless – Horizon Family Clinic
  • Community Servings – Food is Medicine Program
  • Inner City Weightlifting – Grow and Strengthen Core Program
  • Health Leads – Catalyzing Hyper-Local Health Systems Transformation Program
  • Urban Edge – Strong Start Roxbury Program

Supporting Healthier Environments

The following organizations are receiving funding for climate resiliency initiatives building toward a healthier environment:

  • American Red Cross – Annual Disaster Giving Fund Program
  • CitySprouts – Young Leaders Program
  • Mystic River Watershed Association – Wicked Hot Mystic Program

Learn more about Takeda’s U.S. Corporate Social Responsibility Program and our philanthropic strategy here. For more details about Takeda’s Global CSR Program, you can find them here.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.


ę Business Wire 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
01/24Takeda to Hold Third Quarter FY2021 Earnings Conference Call
AQ
01/21TAKEDA PHARMACEUTICAL : to Hold Third Quarter FY2021 Earnings Conference Call
PU
01/19Takeda Named Global Top Employer for Fifth Consecutive Year
BU
01/13Denali Therapeutics Shares Fall as FDA Puts Alzheimer's Study Plan on Hold
DJ
01/13Takeda Pharmaceutical Buys Back $434 Million of Shares as Part of Buyback Program Set t..
MT
01/12Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40..
AQ
01/12S.Korea authorises Novavax COVID-19 vaccine, imports Pfizer pills
RE
01/11S.Korea authorizes Novavax COVID-19 vaccine, imports Pfizer pills
RE
01/11Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta T Cell Engager ..
AQ
01/11Takeda Pharmaceutical Says Its Global Brands Are Expected to Hit Revenue Growth Target
MT
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 410 B 29 941 M 29 941 M
Net income 2022 207 B 1 820 M 1 820 M
Net Debt 2022 3 307 B 29 032 M 29 032 M
P/E ratio 2022 24,3x
Yield 2022 5,48%
Capitalization 5 112 B 44 873 M 44 883 M
EV / Sales 2022 2,47x
EV / Sales 2023 2,36x
Nbr of Employees 47 099
Free-Float 98,2%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 282,00 JPY
Average target price 3 944,29 JPY
Spread / Average Target 20,2%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED6.47%45 679
JOHNSON & JOHNSON-4.73%429 034
ROCHE HOLDING AG-9.06%304 714
PFIZER, INC.-12.72%289 287
ABBVIE INC.-2.39%233 643
ELI LILLY AND COMPANY-12.00%217 963